News

Tyvaso boosts lung function in IPF trial, per top-line data

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…

UK approves Phase 2 trial for IPF therapy candidate LTI-03

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important…

KL-6 protein levels may predict symptom worsening in IPF: Study

Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may help predict acute exacerbations in people with idiopathic pulmonary fibrosis (IPF) and other types of fibrotic interstitial lung diseases (ILDs), a study reports. Findings indicated that KL-6 levels tended…

Machine learning helps construct diagnostic models for IPF

Researchers in China used machine learning — a type of artificial intelligence in which computers detect patterns in datasets and then make predictions — to create diagnostic and prognostic models for use in idiopathic pulmonary fibrosis (IPF). Using the new models, the team observed gene activity changes suggestive of…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums